RxDoctor Payments Data

Marla Lepley-Starr

Psychiatric/Mental Health · Albemarle, NCNPI 1275227969

Payments from drug & device makers

$630in general payments, 2019–2025

Across 27 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$363
  • Johnson & Johnson$102
  • Otsuka America Pharmaceutical, Inc.$72
  • Axsome Therapeutics, Inc.$24
  • Neurocrine Biosciences, Inc.$22
  • AbbVie$17
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$630100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$630 in reported general payments places this provider in the 55th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$11,897
Medicare patients
39
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$152,630
Invega SustennaPaliperidone Palmitate32$107,767
Abilify MaintenaAripiprazole14$42,606
VraylarCariprazine Hcl21$39,237
CaplytaLumateperone Tosylate16$28,537
RexultiBrexpiprazole12$18,125
Asenapine Maleate14$2,522
Ramelteon16$2,429
Vilazodone Hcl11$1,121
Aripiprazole27$894
Bupropion XlBupropion Hcl32$659
Divalproex Sodium18$615
Hydroxyzine Pamoate33$594
Lamotrigine93$589
Buspirone Hcl49$580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$22$152,63020 claims
Johnson & JohnsonInvega Sustenna$102$107,76732 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$72$60,73126 claims
AbbVieVraylar$17$39,23721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Albemarle

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →